← All trials
NCT06576765
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 8, 2024
- Primary completion
- Nov 27, 2024
- Completion date
- Nov 27, 2024
- First posted
- Aug 29, 2024
- Last posted
- Oct 29, 2024
- Enrollment
- 32
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.